Titan Pharmaceuticals (Titan Pharmaceuticals) ROCE % : -104.55% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Titan Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was -104.55%.

Titan Pharmaceuticals ROCE % Historical Data

The historical data trend for Titan Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals ROCE % Chart

Titan Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-78.76

-150.24

-203.59

-303.12

-180.35

Titan Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-411.67	-1,181.55	-	-232.26	-104.55

Titan Pharmaceuticals ROCE % Calculation

Titan Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.277	/	( ( (4.058 - 2.63)	+	(8.086 - 1.444) )	/ 2 )
	=	-7.277	/	( (1.428	+	6.642)	/ 2 )
	=	-7.277	/	4.035
	=	-180.35 %

Titan Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-7.724	/	( ( (9.999 - 1.866)	+	(8.086 - 1.444) )	/ 2 )
	=	-7.724	/	( ( 8.133	+	6.642 )	/ 2 )
	=	-7.724	/	7.3875
	=	-104.55 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Titan Pharmaceuticals (NAS:TTNP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Titan Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TN70:Germany

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Executives

Seow Gim Shen	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd.	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo	director	1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey	director	3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg	director	710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi	director	44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe	director, officer: President and COO	400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong	10 percent owner	NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar	director, 10 percent owner, officer: Chief Executive Officer	VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc	other: Member of 10% owner group	1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers	director	630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin	director, officer: Executive Chairman	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg	officer: See Remarks	400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080